TOTakehisa Ogura

Takehisa Ogura

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Takehisa Ogura has a total of 54 co-authors. Here are the top co-authors by number of shared publications:

  • Hideto Kameda

    Division of Rheumatology, Department of Internal Medicine, Toho University

    6 shared publications
  • Chihiro Imaizumi

    Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University , Tokyo

    3 shared publications
  • Chihiro Imaizumi

    Division of Rheumatology, Department of Internal Medicine, Toho University

    3 shared publications
  • Ayako Hirata

    Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Tokyo, Japan

    2 shared publications
  • Hideki Ito

    Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Tokyo, Japan

    2 shared publications
  • Reina Maezawa

    Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Tokyo, Japan

    2 shared publications

Latest Publications

  • Open Access

    Successful treatment of refractory myositis-associated interstitial lung disease with an interleukin-6 inhibitor: four-patient case series

    by Chihiro Imaizumi, Reina Maezawa, Yasuto Minegishi, Takehisa Ogura, Hideto Kameda

    1. Interstitial lung disease (ILD) is a major cause of mortality in dermatomyositis (DM) and polymyositis (PM) [1]. Notably, many patients with antimelanoma differentiation-associated gene 5 (MDA5)...

  • Open Access

    Clinical characteristics and severity classification in mixed connective tissue disease: a nationwide retrospective study

    by Satoshi Kubo, Yurie Kanda, Hideto Kameda, Masataka Kuwana, Hidehiko Narazaki, Takao Fujii, Keishi Fujio, Yoshinao Muro, Konomi Akamatsu, Koichiro Ohmura, et al.

    Objectives: To characterize clinical manifestations, major organ involvement, real-world treatment patterns and factors associated with severity classification in Japanese patients with mixed connective tissue disease (MCTD), aiming to clarify its heterogeneous clinical spectrum. Methods: This nationwide retrospective multicentre study analyzed clinical data from 249 patients who strictly fulfilled the 2019 Japanese Ministry of Health, Labour and Welfare diagnostic criteria for MCTD, derived from an initial real-world registry of 311 clinically diagnosed patients. Clinical features, autoantibodies and therapeutic regimens were summarized and compared between patients with severe vs nonsevere disease. Results: The cohort was 93.1% female (median onset age 40.6 years). Common findings, specifically Raynaud’s phenomenon and/or swelling of the fingers or dorsum of the hands, were present in 100%. Phenotypically, an overlap of systemic lupus erythematosus (SLE)-like and systemic sclerosis (SSc)-like features was most frequent (56.0%), while 32.0% had manifestations across all three phenotypic domains (SLE-, SSc- and IIM-like). Major organ involvement occurred in 32.9% of patients, including pulmonary arterial hypertension in 12.8%. Approximately 28.7% of evaluable patients were classified as severe. Off-scale-high anti-U1-RNP antibody status was not associated with severity classification (P = 0.492) or with broad phenotypic categories. Glucocorticoids and immunosuppressive agents were used in 66.7% and 56.5% of the patients, respectively. Conclusions: Mixed connective tissue disease exhibits marked clinical heterogeneity. Severity classification was not associated with off-scale-high anti-U1-RNP antibody status or broad phenotypic categories. These findings support rigorous cardiopulmonary screening and management tailored to the dominant clinical phenotype.

  • Tocilizumab for refractory cerebral arteritis in a patient with systemic lupus erythematosus

    by Yasuto Minegishi, Takehisa Ogura, Chihiro Imaizumi, Reina Maezawa, Takafumi Uchi, Hideto Kameda

    Cerebral arteritis is a rare (<1%) but life-threatening manifestation of systemic lupus erythematosus (SLE). The optimal treatment for cerebral arteritis in refractory cases remains unclear; conventional immunosuppressive therapy results in an improvement in arterial stenosis in only 29% of reported cases. We report the case of a 51-year-old woman with a 20-year history of SLE and rheumatoid arthritis who developed aphasia and right hemiparesis due to a haemodynamic cerebral infarction caused by cerebral arteritis. Despite treatment with high-dose glucocorticoids, intravenous cyclophosphamide, mycophenolate mofetil, and anifrolumab, the disease remained progressive with persistently elevated C-reactive protein levels and worsening arterial stenosis on magnetic resonance angiography. Cerebrospinal fluid interleukin-6 level was markedly elevated (1590 pg/ml). After switching from anifrolumab to tocilizumab, C-reactive protein levels normalised, the patient’s neurological condition stabilised, and follow-up magnetic resonance angiography suggested an improvement in arterial stenosis. Tocilizumab might be a viable treatment option for refractory cerebral arteritis in patients with SLE, particularly in cases with elevated cerebrospinal fluid interleukin-6 levels. To our knowledge, this is the first reported case suggesting the potential efficacy of tocilizumab in SLE-related cerebral arteritis.

  • Development of the Japan College of Rheumatology guidance on musculoskeletal ultrasound scanning protocol in rheumatology practice (revised edition)

    by Takehisa Ogura, Kei Ikeda, Shin-Ya Kawashiri, Michihiro Ogasawara, Tadashi Okano, Makoto Wada, Tatsunori Horie, Ryusuke Yoshimi, Ryuichi Nakahara, Ryota Hara, et al.

    Objectives: To describe the methodological framework and consensus-based decision rules that underpin the revised guidance on musculoskeletal ultrasound scanning protocols in rheumatology practice. Methods: A systematic literature search on musculoskeletal ultrasound imaging and assessment methods was conducted to extract candidate anatomical structures and their corresponding scanning techniques from the included articles. A Delphi survey of the Guidance Development Panel selected the sites for inclusion. Iterative consensus meetings defined standardised scanning procedures for each structure, including patient positioning, limb orientation, probe placement, scanning direction, and the key anatomical landmarks to be captured on the ultrasound images. Results: A total of 3168 unique records were identified, of which 36 were included after screening. Based on the included articles and the first edition, a list of 159 candidate anatomical structures across the seven regions was compiled (including two structures added during the consensus process). Through the Delphi process, 50 structures were endorsed for inclusion. An image atlas was produced presenting the standardised views used in routine practice and the scanning procedures for the recommended structures. Conclusions: This revised guidance provides standardised musculoskeletal ultrasound scanning methods for rheumatic diseases based on a systematic literature search and a structured consensus process.

  • Open Access

    Ultrasound evaluation of finger joint cartilage damage progression in patients with rheumatoid arthritis

    by Takehisa Ogura, Chihiro Imaizumi, Ayako Hirata, Yasuto Minegishi, Hideki Ito, Sayaka Takenaka, Takaharu Katagiri, Yuto Takakura, Reina Maezawa, Hideto Kameda

    Background: Cartilage damage in rheumatoid arthritis (RA) is commonly evaluated by joint space narrowing (JSN) on conventional radiograph (CR). Cross-sectional studies suggest that ultrasound (US) can directly assess finger-joint cartilage damage; however, whether it can sufficiently evaluate cartilage changes over time remains unclear. Objectives: This study aimed to investigate temporal changes in cartilage damage in patients with RA using US. Design: A single-center, retrospective observational study. Methods: Fifty-three patients with RA underwent US scans of finger joints and CR of both hands at baseline and 1 year later. Cartilage thickness was measured at the bilateral second to fifth metacarpophalangeal and proximal interphalangeal joints, and cartilage damage was semiquantitatively scored using recorded US images. JSN was scored on CR using the van der Heijde-modified Sharp method. Patients were grouped by disease activity over 1 year, assessed by Disease Activity Score of 28 joints with C-reactive protein. Continuous variables were analyzed using the Mann–Whitney U or Wilcoxon signed-rank test. Correlations were assessed using Spearman’s rank correlation coefficients. Results: Median patient age and disease duration were 68 and 6.3 years, respectively. Baseline total cartilage thicknesses of 16 joints ranged from 3.1 to 9.1 mm (median, 6.5 mm). Total semiquantitative scores were 0–22 (median, 5). Cartilage thickness (rho, −0.63; p < 0.001) and semiquantitative (rho, 0.67; p < 0.001) scores were significantly correlated with JSN scores. Patients with sustained moderate-to-high disease activity showed greater cartilage thickness reduction (median, −6.2%) than others (median, −1.2%; p = 0.004), although semiquantitative (21.6% vs 16.7%, p = 0.74) and JSN (0% vs 0%, p = 0.68) scores remained unchanged. The two groups differed significantly in the amount of change (−0.4 vs −0.1 mm, p = 0.006). Conclusion: US detected cartilage damage progression in RA over 1 year, supporting its usefulness for longitudinal assessment.

  • Open Access

    Cartilage evaluation by ultrasonography in patients with rheumatoid arthritis: a scoping review

    by Takehisa Ogura, Takaharu Katagiri, Hideto Kameda

    Background: This study aimed to provide an overview of ultrasonographic cartilage evaluation in patients with rheumatoid arthritis (RA) and identify research gaps in the utilization of cartilage evaluation. Methods: The study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews guidelines. A systematic literature search of the PubMed, Embase, and Cochrane Library databases was conducted for articles published up to July 2022 using the search term variations of “cartilage,” “ultrasonography,” and “rheumatoid arthritis.” Studies that included patients with RA who underwent cartilage evaluation by ultrasonography were selected. Articles published in languages other than English and about juvenile idiopathic arthritis were excluded. Results: Twenty-nine articles were identified. Most were cross-sectional studies (86%), mainly involving the metacarpophalangeal (55%) and knee (34%) joints. Assessments were performed using quantitative, binary, and semi-quantitative methods in 15, 10, and 15 studies, respectively. Reliability assessments were conducted in 10 studies, which showed feasible reliability but were limited to the finger joints. The validity assessment was validated in one study each that compared cartilage thickness measurements with cadaveric specimens and histological and semi-quantitative methods with surgical specimens, respectively. Comparisons with conventional radiography were also performed in six studies, which showed significant correlations. However, there was heterogeneity in the examination and assessment methods, and no adequate longitudinal evaluation was conducted. Conclusion: This review highlights the need for further research and validation of ultrasonographic cartilage assessment in patients with RA.


  • Open Access

    Reduced Rate of Disease Flares in Japanese Patients with Systemic Lupus Erythematosus: An Altered Balance between the Use of Glucocorticoids and Immunosuppressants in Recent Decades

    by Chihiro Imaizumi, Takehisa Ogura, Yuki Inoue, Yuto Takakura, Takaharu Katagiri, Sayaka Takenaka, Hideki Ito, Kennosuke Mizushina, Ayako Hirata, Hideto Kameda

    Objective This study examined whether or not the disease control in Japanese patients with systemic lupus erythematosus (SLE) had improved in recent years and its possible association with altered balance between the use of glucocorticoids and immunosuppressants. Methods We enrolled Japanese patients with SLE who visited our medical center during 2013-2017 (Group A, 75 patients) and compared them with patients encountered during 1999-2003 (Group B, 69 patients; not overlapping with Group A). Patient background characteristics, doses of glucocorticoids, and the use of immunosuppressants at the times of SLE onset and disease flares were reviewed from the medical records. Disease flare was defined as new British Isles Lupus Assessment Group 2004 A or B scores in at least one system. Results Lupus nephritis and neuropsychiatric manifestations were less frequently observed in Group A than in Group B (p=0.042 and p=0.045, respectively). Although the initial glucocorticoid dosage was similar between the groups, the inclusion rate of immunosuppressants in the initial SLE treatment was significantly higher in Group A than in Group B (56% vs. 6% in Group B, p<0.001). The median number of SLE flares per person-year was significantly lower in Group A than in Group B (0 vs. 0.3, respectively, p<0.001), and a propensity score-matched analysis indicated the association of SLE flare with the non-use of immunosuppressants in the initial treatment (p=0.012). The rates of infectious diseases and other complications were similar between the groups. Conclusion The recent aggressive use of immunosuppressants in Japan resulted in a reduction in the rate of SLE flare.